SCHEMBL5607371

SCHEMBL5607371

Cc1ccc(Oc2ccccc2-c2nn[nH]n2)c(O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.52
PKM P14618 1/20 0.52
GAA P10253 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
ALDH1A1 P00352 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
XDH P47989 1/20 0.46
POLB P06746 1/20 0.44
IDO1 P14902 3/20 0.43
PBRM1 Q86U86 1/20 0.43
LDHA P00338 1/20 0.43
MAP3K8 P41279 1/20 0.42
NR1I2 O75469 1/20 0.42
CYP2C9 P11712 1/20 0.42
KCNH2 Q12809 1/20 0.42
CHRM2 P08172 1/20 0.41
DRD2 P14416 1/20 0.41
DRD3 P35462 1/20 0.41
TAS2R14 Q9NYV8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5607474 0.86 CASP6 (0.53) KDM4EPKMGAAMEN1KMT2A
SCHEMBL5606179 0.84 MEN1 (0.59) KDM4EPKMGAAMEN1KMT2A
SCHEMBL5607418 0.84 IDO1 (0.59) KDM4EPKMGAAMEN1KMT2A
SCHEMBL5607695 0.80 KDM4E (0.65) KDM4EPKMGAAMEN1KMT2A
SCHEMBL5607393 0.79 XDH (0.51) GAAKMT2AALDH1A1L3MBTL1XDH
SCHEMBL5607912 0.78 KMT2A (0.38) GAAMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL5606986 0.76 PBRM1 (0.50) KDM4EPKMGAAMEN1KMT2A
SCHEMBL5607036 0.75 CASP6 (0.41) MEN1KMT2AALDH1A1L3MBTL1IDO1
SCHEMBL7546534 0.75 CA1 (0.48) GAAIDO1
SCHEMBL5607545 0.74 IDO1 (0.60) KDM4EPKMIDO1NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1838300-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS Emergent Product Development Gaithersburg Inc. (US) 2007-10-03 EP claimed
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. 2006-09-21 US claimed
WO-2006071471-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2006-07-06 WO claimed
EP-1838300-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS Emergent Product Development Gaithersburg Inc. (US) 2007-10-03 EP disclosed
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. 2006-09-21 US disclosed
WO-2006071471-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents TYR, NFE2L2, CYP1A1 KDM4E 1823/4885PKM 2518/4885GAA 2189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.